The Nasdaq closed at a record 27,477.31 on Monday, yet the 10-year Treasury yield pushed to a fresh 52-week high near 5.3%. That tension frames the stocks to watch tomorrow. Four companies report on Tuesday, a vaccine maker that soared on Phase 3 data is launching a $1 billion offering, and an AI-infrastructure favorite heads into earnings with a negative year-to-date return. Here are 10 names, from a beaten-down beer giant to small caps most investors have never traded, with the levels that matter for the Tuesday, October 6 session.
Stocks to Watch Tomorrow: Monday’s Market Snapshot
| Metric | Monday Close / Reading |
|---|---|
| S&P 500 | 7,773.95 (+0.66%) |
| Nasdaq Composite | 27,477.31 (+1.05%), record close |
| Dow Jones Industrial Average | 51,267.90 (+0.18%) |
| Russell 2000 | 2,853.27 (+0.72%) |
| 10-Year Treasury Yield | ~5.31%, a new 52-week high |
| Oil | WTI near $90, Brent near $103 in morning trade |
| Macro Backdrop | Fed hiked in September; September payrolls added just 29,000 jobs |
The Nasdaq finished at a record as tech led the tape, while the 10-year yield rose to a new 52-week high with the selloff concentrated at the long end. Fed minutes from the September hike land Wednesday, and the trade balance is the main data point Tuesday. That leaves company news in charge of the session.
Data note: Closes are Monday, October 5 figures from exchange-linked sources. Where no single authoritative close was available, we say “near” or “roughly.” RSI and MACD are omitted where feeds carried stale timestamps. Support and resistance levels are analytical zones built from verified closes, intraday ranges, 52-week extremes, moving averages and analyst targets, not guaranteed targets.
Tomorrow’s Earnings Calendar: Stocks to Watch Before the Open and After the Bell
| When | Ticker | Consensus EPS | Revenue Estimate |
|---|---|---|---|
| Tue, before the open (~8:00 a.m. ET) | LW | ~$0.58–$0.59 | ~$1.65B |
| Tue, after the close | STZ | ~$3.55–$3.62 | ~$2.54–$2.57B |
| Tue, after the close | PENG | $0.75 (whisper $0.84) | $512.5M |
| Tue, after the close | NEOG | $0.05 | ~$208M |
| Wed, after the close | APLD | Loss expected | ~$135M |
Per the Earnings Whispers calendar and Kiplinger’s weekly preview, these are the notable reports for the next two sessions.
1. Lamb Weston (LW) | Last Close $44.58 (+2.2%) | Earnings Before the Open
The French Fry King Reports After a 5.9% Friday Pop and a Round of Target Cuts
Lamb Weston reports fiscal Q1 results before the opening bell Tuesday, with Wall Street expecting EPS to fall to about $0.59 from $0.74 a year ago.
| Metric | Value |
|---|---|
| Last Close | $44.58 (Friday close: $43.60) |
| Day’s Move | +2.2% (Friday: +5.88%) |
| 52-Week Range | $37.62 – $67.07 |
| Market Cap | ~$6.1B |
| P/E (TTM) | ~20.8x |
| Dividend | $1.52/yr (~3.5% yield) |
| Volume vs. Average | Not final at press time |
| Analyst Consensus | Hold; average target ~$52.91 |
| Q1 Consensus | EPS ~$0.58–$0.59; revenue ~$1.65B (flat) |
| FY27 EPS Guidance | $2.95–$3.25 |
| Support 1 / 2 / 3 | $43.60 / $41.00 / $37.62 |
| Resistance 1 / 2 / 3 | ~$45.89 (200-day) / $46.00 / ~$50.00 |
Catalyst & Latest News: Stephens cut its target to $50 from $55 on Monday, and Wells Fargo trimmed to $54. Pressure points include carryover potato costs, elevated edible-oil costs and weaker price and mix.
Technicals: The stock bounced from a $40.85 low on Friday but still trades below its roughly $45.89 200-day average and far under its ~$50.78 50-day.
Fundamentals: July’s Q4 EPS of $0.87 beat the $0.63 estimate and sent shares up 16%. Beta is a defensive 0.47.
Bull Case: A fresh beat, a reaffirmed guide and a stock about 35% off its high could squeeze shorts. Bear Case: The Street expects earnings to fall roughly 20% year over year, 11 of 14 analysts say Hold, and a governance probe lingers.
What to Watch:
- Whether the $2.95–$3.25 FY27 EPS guide holds
- Volume growth versus price and mix
- Commentary on potato and oil costs
Forecast: A beat plus a held guide opens $46, then $50. A miss that loses $41 points toward the 52-week low near $37.62.
Why This Matters: Lamb Weston is the cleanest read on restaurant fry volumes and input-cost pass-through, a signal for every foodservice name.
2. Constellation Brands (STZ) | Last Close ~$113 (Flat) | Earnings After the Bell
Corona’s Maker Hits an 11-Year Low and Reports With a 5.4% Move Priced In
Constellation Brands touched $110.60 on Monday, its lowest level since January 2015, then steadied near $113 ahead of fiscal Q2 results after the bell.
| Metric | Value |
|---|---|
| Last Close | ~$113 (essentially flat; Friday ~$113.0) |
| Day’s Move | ~0% (intraday low $110.60, high ~$113.80) |
| 52-Week Range | ~$110.60 – $168.60 |
| Market Cap | ~$19.3B |
| P/E (TTM) | ~10.8x (EPS $10.50) |
| Dividend | $4.12/yr (~3.65% yield) |
| Volume vs. Average | Average ~2.0M shares; final tally not confirmed |
| YTD / 1-Year | ~-19% / ~-22% |
| Analyst Consensus | Hold; average target ~$157–$163 |
| Q2 Consensus | EPS ~$3.55–$3.62; revenue ~$2.54–$2.57B |
| Options-Implied Move | ±5.4% (~$107–$119) |
| Support 1 / 2 / 3 | $110.60 / ~$107 / $105 |
| Resistance 1 / 2 / 3 | ~$113.80 / ~$117–$118 / ~$122 |
Catalyst & Latest News: UBS sees Q2 EPS at $3.33, below the $3.54 consensus, and Wells Fargo cut its target to $140 from $170. Brazil’s election lifted Ambev about 10%, but STZ barely moved.
Technicals: Shares sit at the bottom of a range that began near $168.60, and the $110.60 print is the line bulls must defend.
Fundamentals: Q1 EPS of $3.43 beat $3.22, beer net sales rose 2% to $2.28B, and beer margin held near 39%. FY27 comparable EPS guidance is $11.20–$11.90, with organic sales flat.
Bull Case: About 10x earnings, a 3.65% yield and four straight EPS beats. The stock has risen after five of its last six reports. Bear Case: Soft depletions (Modelo Especial -2%, Corona Extra -5% in recent data), tariff costs and a string of target cuts.
What to Watch:
- Beer depletions and shipments versus the ±1% sales guide
- Whether the EPS range is reaffirmed
- Tariff and cost commentary on Wednesday’s 8:00 a.m. ET call
Forecast: Holding $110.60 with a clean guide could push shares toward $117–$118. A break lower targets $105.
Why This Matters: STZ is a live test of whether the premium-beer consumer can hold up with 10-year yields above 5%.
3. Penguin Solutions (PENG) | Last Close ~$61.6 (+0.4%) | Earnings After the Bell
An AI Memory Play Up Nearly 4x From Its March Low Faces a $0.84 Whisper Number
Penguin Solutions reports fiscal Q4 after the close, with a $0.75 consensus and a $0.84 whisper.
| Metric | Value |
|---|---|
| Last Close | ~$61.6 (Friday close: $61.36) |
| Day’s Move | +0.4% (range $59.28 – $61.87) |
| 52-Week Range | $16.04 – $89.86 |
| Market Cap | ~$3.16B |
| P/E | ~26.9x (normalized) |
| Dividend | None |
| Volume vs. Average | ~1.0M vs. ~3M average (light) |
| Q4 Consensus | EPS $0.75 (whisper $0.84); revenue $512.5M (+~52%) |
| FY26 Guidance | EPS $2.55–$2.65; revenue $1.64–$1.70B |
| Beta | ~2.9 |
| Support 1 / 2 / 3 | $59.28 / $56.22 / $53.08 |
| Resistance 1 / 2 / 3 | ~$61.90 / $65.00 / $70.00 |
Catalyst & Latest News: Investors want a first look at the fiscal 2027 outlook after management previewed roughly 30% sales and earnings growth. Shares have lost about 17% since the last report despite two guidance raises.
Technicals: The stock trades near the low end of its post-earnings range of $43.61–$89.86 but above its 200-day average, per Earnings Whispers.
Fundamentals: Last quarter’s record $478.7M revenue included memory sales that more than doubled. Management warned of gross margin below 28.1%, operating cash flow was -$75M, and convertible dilution lifts the share count toward 62 million. Morningstar data shows a $3.16B market cap.
Bull Case: Non-hyperscale AI infrastructure grew 81% last quarter, and the whisper suggests the bar is higher than published. Bear Case: Memory pricing is fading, margins are slipping, cash flow turned negative and the CFO search continues.
What to Watch:
- FY27 growth preview and gross margin versus the 28.5% full-year target
- Operating cash flow reversal
- Share count and dilution
Forecast: A beat above $0.84 with a firm FY27 outlook could lift $65–$70. Disappointment on margins puts $56 and then $53 in play.
Why This Matters: Penguin is a clean read on whether AI memory strength is price or share gain.
4. Neogen (NEOG) | Last ~$13.0 (+7%) | Earnings After the Bell, Investor Day Wednesday
A 7% Pop Into the Print, With an FDA Warning Letter Still Hanging Over the Stock
Neogen jumped about 7% Monday to roughly $13.0 and reports fiscal Q1 after the close, followed by an investor day.
| Metric | Value |
|---|---|
| Last Price | ~$13.0 (Friday close: $12.15) |
| Day’s Move | +~7% (range $11.98 – $13.24) |
| 52-Week Range | $5.37 – $14.26 |
| Market Cap | ~$2.8B |
| P/E | Negative TTM EPS (-$0.04); forward ~44x |
| Dividend | None |
| Volume vs. Average | ~5.2M vs. ~5.7M average |
| YTD | ~+85% |
| Analyst View | Guggenheim Buy, $14 target; Piper Sandler Overweight, $14 |
| Q1 Consensus | EPS $0.05; revenue ~$208M; company guide $207–$209M |
| Short Interest | ~10.6M shares (4.9% of float) |
| Support 1 / 2 / 3 | $12.15 / $11.98 / ~$11.70 |
| Resistance 1 / 2 / 3 | $13.24 / ~$13.98 / $14.26 |
Catalyst & Latest News: The FDA warned Neogen over a contaminated sterile veterinary product tied to nearly 100 sick horses, and the agency gave the company 15 working days to respond. Shares fell more than 5% on September 29 before recovering.
Technicals: Monday’s rebound reclaimed the Friday close but sits below the September high.
Fundamentals: July’s Q4 brought EPS of $0.09 versus $0.06 expected and revenue of $225.3M versus $212.4M. FY27 revenue guidance of $880–$885M topped the $849M consensus. Securities class actions over the 3M integration remain open.
Bull Case: Beat-and-raise history, Guggenheim calling the selloff overdone, and short interest that can fuel a squeeze. Bear Case: Regulatory escalation risk, remediation costs and a stock up about 85% this year.
What to Watch:
- Any HYCOAT remediation costs or legal reserves
- Investor Day targets, Wednesday at 9:00 a.m. ET in New York
- Whether FY27 revenue guidance is raised
Forecast: A clean quarter with confident margin targets could challenge $13.98–$14.26. Fading back under $12 would leave a gap-fill toward $11.70.
Why This Matters: Neogen shows how quickly a quality-control failure can reshape a turnaround story.
5. Vaxcyte (PCVX) | Prior Close $56.48 | Midday ~$74–$78 (+32% to +37%) | $1 Billion Offering in Play
A Phase 3 Home Run, Then a $1 Billion Raise: The Day’s Most Violent Reversal
Vaxcyte gapped to about $87 at the open, hit roughly $90.70, then faded to the mid-$70s by midday. We could not confirm the final close.
| Metric | Value |
|---|---|
| Prior Close | $56.48 (Friday) |
| Monday | Open ~$87.2; high ~$90.7; midday ~$74.50–$77.65 |
| Day’s Move | +32% to +37% at midday (final close not confirmed) |
| 52-Week Range | $39.87 – ~$90.7 (new high Monday) |
| Market Cap | ~$11–12B (148.8M shares) |
| P/E / Dividend | Not meaningful (pre-revenue) / None |
| Volume vs. Average | ~5.8M by midday vs. ~1.2M average |
| Analyst Targets | Guggenheim $125 (from $116); BofA $130 |
| Cash | ~$1.49B at last report |
| Support 1 / 2 / 3 | ~$74–$75 / $65.00 / $56.48 |
| Resistance 1 / 2 / 3 | ~$78–$80 / ~$87–$88 / ~$90.70 |
Catalyst & Latest News: Vaxcyte’s 4,047-patient OPUS-1 trial met all primary endpoints, with noninferiority on all 28 shared serotypes and superiority on four comparisons. Guggenheim lifted its target to $125. The company also launched a proposed $1 billion offering of stock, pre-funded warrants and convertible notes, likely a factor in the fade.
Technicals: A spike above $90 that reversed into the mid-$70s is a textbook intraday sell-the-news pattern, and where the stock settled will set Tuesday’s tone.
Fundamentals: BLA filing is planned for the first half of 2028, with OPUS-2 and OPUS-3 data due in the first half of 2027. Trailing EPS is about -$7.65.
Bull Case: Best-case data against Prevnar 20 and Capvaxive in a multibillion-dollar market. Bear Case: Dilution from the raise, two of 19 PCV21-shared serotypes missing the bar, and a 2028 filing.
What to Watch:
- Offering size, price and discount
- Whether $74–$75 holds
- Further target hikes
Forecast: A tight offering discount could stabilize shares above $74, while a wide one risks a gap toward $65.
Why This Matters: Vaxcyte shows how even a perfect readout can meet financing-driven selling.
6. Applied Digital (APLD) | Last Close ~$24.3 (-4.4%) | Earnings Wednesday After the Bell
Dan Loeb Buys In and Options Price a 13.6% Swing, but the Stock Slides Into the Print
Applied Digital reports Wednesday after the close, and traders priced a swing of roughly 13.6%, or about $3.44.
| Metric | Value |
|---|---|
| Last Close | ~$24.3 (Friday close: $25.38) |
| Day’s Move | -~4.4% (range $24.22 – $25.63) |
| 52-Week Range | $19.00 – $50.72 |
| Market Cap | ~$7.3B |
| P/E / Dividend | Negative EPS (-$0.91) / None |
| Volume vs. Average | ~15.0M vs. ~17.4M average |
| YTD | Roughly flat to slightly negative |
| Analyst Targets | Consensus ~$60–$66; low $22 (Redburn), high ~$109 |
| Q1 Consensus | Revenue ~$135M vs. $258.7M last quarter |
| Support 1 / 2 / 3 | $24.22 / $22.00 / $19.00 |
| Resistance 1 / 2 / 3 | $25.38 / $25.63 / ~$27.5–$28 |
Catalyst & Latest News: Applied Digital brought another 75 MW online at Polaris Forge 1, lifting operational capacity to 250 MW. Billionaire Dan Loeb disclosed a stake, and Jones Trading started coverage at Buy with a $70 target while UBS and Redburn weighed in. TNN flagged the lease pipeline in September.
Technicals: Shares are about half their May high and sit near their 52-week lows’ upper range after a sector-wide AI hosting selloff, with extreme beta.
Fundamentals: About $36 billion in long-term leases across five campuses sits against roughly $5 billion of debt. The expected revenue drop reflects timing rather than demand, per Motley Fool.
Bull Case: Contracted backlog and operating MW are converting to revenue. Bear Case: Heavy debt, negative EPS and 10-year yields near 5.3%.
What to Watch:
- Revenue versus the roughly $135M estimate
- New lease announcements
- Financing costs and capex plans
Forecast: Holding $24.22 into the print keeps the setup alive. A break under $22 would test the $19 low.
Why This Matters: APLD is the sector’s proxy for how much leverage the market will tolerate.
7. TeraWulf (WULF) | Last Close $14.79 (-4.5%) | Sold Despite Doubling Power to 1 GW
Bigger Power Contract, Smaller Share Price: The Market Wants Proof, Not Megawatts
TeraWulf doubled contracted power at its Muskie Data Campus to 1 gigawatt, yet shares fell 4.52% to $14.79.
| Metric | Value |
|---|---|
| Last Close | $14.79 (Friday close: $15.49) |
| Day’s Move | -4.52% (-$0.70) |
| 52-Week High | $29.84 (about 50% above) |
| Market Cap | ~$7.4B (estimated from ~500M shares) |
| P/E / Dividend | Negative earnings / None |
| Volume vs. Average | Average ~28.9M shares (early September data) |
| YTD | ~+28% |
| Analyst Targets | Consensus ~$31.70–$33.69; range $15–$62.50 |
| Valuation | Price-to-sales ~39.8x |
| Support 1 / 2 / 3 | ~$14.60 / $14.00 / ~$13.50 |
| Resistance 1 / 2 / 3 | $15.49 / ~$16.00 / ~$17.00 |
Catalyst & Latest News: The second 500 MW phase was pulled forward to 2029 from 2030, but the expansion needs Kentucky regulatory approval. TeraWulf called customer interest tremendous.
Technicals: The stock gave up Friday’s $15.49 close despite good news, a sign of sector-wide AI infrastructure fatigue.
Fundamentals: The deal includes about $100 million in customer benefits over a decade and financing support for a 760 MW Kentucky Power gas plant.
Bull Case: Up to 2 GW of potential power is rare and valuable for hyperscale demand. Bear Case: Regulators must still approve, revenue is years away and the valuation is rich.
What to Watch:
- A hold of $14.60
- Kentucky PSC timeline
- A new tenant announcement
Forecast: Reclaiming $15.49 would signal the selloff is exhausted. A break under $14 targets $13.50.
Why This Matters: Power is the bottleneck of AI, and WULF shows how skeptical the market has become of long-dated capacity.
8. DraftKings (DKNG) | Last ~$19.6 (+~5%) | Oversold Bounce After a BofA Upgrade
Down 46% for the Year, DraftKings Bounces From a Three-Year Low on a Prediction-Market Bet
Bank of America upgraded DraftKings to Buy with a $27 target, and shares rebounded from Friday’s $18.52 three-year low.
| Metric | Value |
|---|---|
| Last Price | ~$19.6 late in the session (Friday close: $18.59) |
| Day’s Move | +~5% (intraday high near +8%) |
| 52-Week Range | $18.52 – $36.98 |
| Market Cap | ~$16B |
| P/E | ~22x forward |
| Dividend | None |
| Volume vs. Average | Not final at press time |
| YTD | ~-46% |
| Analyst Consensus | Buy; average target ~$34–$35; BofA $27 |
| Short Interest | 8.3% of float |
| Support 1 / 2 / 3 | $19.00 / $18.52 / $17.50 |
| Resistance 1 / 2 / 3 | ~$20.00 / $21.00 / ~$22.00 |
Catalyst & Latest News: BofA called prediction markets a win-win, estimating $400 million in 2027 fees plus $200–$400 million from market making. It cut 2026 adjusted EBITDA to $500M from $625M. TNN tracked the stock’s slide into August earnings.
Technicals: RSI sat at 13.7 on Friday, deep in oversold territory, and the put/call ratio ranks in the 80th percentile.
Fundamentals: Q2 EPS of $0.09 beat $0.02, but revenue of $1.44B fell 4.6%.
Bull Case: NFL season volume, prediction-market upside and short covering. Bear Case: Revenue is shrinking, margin investment is rising and prediction markets face regulatory risk.
What to Watch:
- A close above $20
- Short covering
- Any state-level prediction-market ruling
Forecast: A break above $21 would confirm a reversal. A close under $19 reopens $18.52.
Why This Matters: DKNG shows how oversold conditions and a single upgrade can reverse a crowded short.
9. Velo3D (VELO) | Last Close ~$9.57 (-14.6%) | CFO Exit Triggers a Midday Plunge
A CFO Departure Sends the Aerospace 3D-Printing Stock Down as Much as 21%
Velo3D’s chief financial officer left on September 28, disclosed in an October 2 filing, and shares crashed Monday.
| Metric | Value |
|---|---|
| Last Close | ~$9.57 (Friday close: $11.20) |
| Day’s Move | -14.6% (intraday low ~$8.62, down as much as ~21%) |
| 52-Week Range | $3.51 – $31.75 |
| Market Cap | ~$0.4B |
| P/E / Dividend | Negative earnings / None |
| Volume vs. Average | Not final at press time |
| Analyst Consensus | Average target ~$21.75 |
| 2026 Guidance | Revenue $60–$70M |
| Support 1 / 2 / 3 | $8.62 / $8.00 / $7.00 |
| Resistance 1 / 2 / 3 | ~$10.00 / $10.38–$11.20 / $11.35 |
Catalyst & Latest News: An interim CFO, Terence Wynn, was named as an outside consultant. The company gave no other reason for the exit, and the next report is due in November.
Technicals: A midday low of $8.62 was followed by a partial recovery to $9.57, and Friday’s $10.38–$11.35 range is now overhead resistance.
Fundamentals: Q1 revenue rose 48% to $13.82 million, and backlog reached $30 million. Management had guided to positive EBITDA in the second half.
Bull Case: Aerospace and defense demand and a stock far above its $3.51 low. Bear Case: Management turnover, past short-seller allegations and thin liquidity.
What to Watch:
- $9.57 as the new pivot
- Any 8-K on a permanent CFO
- Any company commentary on guidance
Forecast: Holding $8.62 could allow a bounce toward $10. A break under $8 risks $7.
Why This Matters: For a small cap with a skeptical short base, finance-chief turnover is a credibility event.
10. Capricor Therapeutics (CAPR) | Last Close ~$7.78 (-13.1%) | FDA Decision Clock Ticks to Nov. 22
New Duchenne Data Meets a Sell-the-News Reaction: Is the Setup Better or Worse?
Capricor presented 24-month HOPE-3 extension data and shares fell as much as 9% during the session, reportedly closing near $7.78, down 13.1% from $8.95.
| Metric | Value |
|---|---|
| Last Close | ~$7.78 (Friday close: $8.95) |
| Day’s Move | -~13% (intraday ~-9.4% at $8.11) |
| 52-Week Range | $2.96 – $40.37 |
| Market Cap | ~$450M (58.1M shares) |
| P/E / Dividend | Negative earnings / None |
| Volume vs. Average | Not final at press time |
| Analyst Target | ~$27 (Buy consensus) |
| Key Date | PDUFA: Nov. 22, 2026 |
| Support 1 / 2 / 3 | $7.50 / $7.00 / $6.80 |
| Resistance 1 / 2 / 3 | ~$8.11–$8.50 / $8.95 / ~$10.00 |
Catalyst & Latest News: Patients who switched from placebo to deramiocel saw a 76% slower rate of upper-limb decline, and the data is already with the FDA. The FDA moved its decision date to November 22. A patient advocacy group webinar on the data is set for Wednesday. TNN’s earlier Capricor forecast covers the background.
Technicals: The close sits well above the $6.80 level where shares traded when the PDUFA date moved, but it gave back the post-extension rally.
Fundamentals: Net loss runs near $129M a year. A securities class action is pending.
Bull Case: Approval would transform the valuation, and durability data is encouraging. Bear Case: The extension data is uncontrolled, and binary FDA risk cuts both ways.
What to Watch:
- The $7.50 level
- The advocacy group webinar
- Any FDA labeling or advisory update
Forecast: Holding $7.50 keeps the November setup intact, while a break below $7 would test $6.80.
Why This Matters: Capricor shows how binary FDA clocks drive volatility far more than any single data release.
Stocks to Watch Tomorrow: Sector Sentiment Snapshot and Forecast
Consumer staples are the weak link: STZ and LW both sit near multi-year lows with cautious analysts, so a beat could spark outsized relief. AI-infrastructure sentiment has soured, as APLD and WULF fell despite positive news while the 10-year yield pressures financing-heavy names. Event-driven healthcare is the busiest corner, with Vaxcyte’s offering, Neogen’s investor day and Capricor’s FDA clock. The forecast for Tuesday is stock-specific, since earnings and offering pricing are likely to matter more than macro until Wednesday’s Fed minutes.
At a Glance: Stocks to Watch Tomorrow (Oct 6, 2026)
| # | Ticker | Last Close / Price | Move | Catalyst | Key Level |
|---|---|---|---|---|---|
| 1 | LW | $44.58 | +2.2% | Q1 earnings, pre-market | $41.00 / $46.00 |
| 2 | STZ | ~$113 | ~0% | Q2 earnings, after close | $110.60 / $117 |
| 3 | PENG | ~$61.6 | +0.4% | Q4 earnings, after close | $59.28 / $65 |
| 4 | NEOG | ~$13.0 | +~7% | Q1 earnings and FDA letter | $12.15 / $13.98 |
| 5 | PCVX | ~$74–$78 midday | +32% to +37% | $1B offering pricing | $74 / $90.70 |
| 6 | APLD | ~$24.3 | -~4.4% | Earnings Wednesday | $24.22 / $25.38 |
| 7 | WULF | $14.79 | -4.52% | 1 GW Muskie expansion | $14.60 / $15.49 |
| 8 | DKNG | ~$19.6 | +~5% | BofA upgrade | $19.00 / $21.00 |
| 9 | VELO | ~$9.57 | -14.6% | CFO exit | $8.62 / $10.00 |
| 10 | CAPR | ~$7.78 | -~13% | PDUFA Nov. 22 | $7.50 / $8.95 |
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and small-cap, clinical-stage biotech, AI-infrastructure and other high-volatility stocks carry elevated risk. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change. Some prices are approximate or based on intraday figures where exact closing data was not available. Support and resistance levels are analytical reference zones, not guaranteed price targets. Analyst price targets and ratings are third-party estimates and do not guarantee actual results. Always complete independent due diligence prior to executing equity trades.
About The Author
